The Evidence-Based Drug Policy Act of 2025 (EBDPA), introduced by Representatives Dina Titus and Ilhan Omar, doesn\u2019t aim to legalize cannabis or reschedule it. Instead, it proposes something deceptively simple: allow the federal government to study it. In a policy environment where ideology has long outpaced data, this quiet shift could have seismic consequences.<\/p>\n
The bill would repeal parts of the 1998 Office of National Drug Control Policy Reauthorization Act that restrict federal funding for studies on Schedule I substances like cannabis, heroin, MDMA, and psilocybin. It would also remove language requiring the ONDCP to actively oppose any efforts to legalize these drugs, opening the door for unbiased, peer-reviewed research to influence future policy.<\/p>\n
While modest in scope, the bill represents a potential turning point. It acknowledges that research is just good governance.<\/p>\n
A Long-Overdue Catch-Up<\/p>\n
The federal government remains stuck in a rhetorical time warp, treating cannabis as if it\u2019s 1985. Cannabis is still classified as a Schedule I drug, implying it has no accepted medical use and a high potential for abuse\u2014despite the fact that millions of Americans use it legally under state medical programs, and a majority of states have legalized some form of adult-use cannabis.<\/p>\n
Representative Omar put it plainly: \u201cWe need drug policy to follow the science and reflect the reality on the ground.\u201d That ground has shifted dramatically, yet federal agencies are still legally blindfolded when it comes to funding or even conducting studies that could inform everything from youth consumption trends to economic equity in legal markets.<\/p>\n
\u201cRight now, there\u2019s no systematic way for the federal government to measure how legalization impacts youth use, arrest rates, or economic opportunity,\u201d said Cat Packer, director of Drug Markets and Legal Regulation at Drug Policy Alliance. \u201cThat institutional blindfold limits our ability to make informed, responsive policy.\u201d<\/p>\n
Why Research Still Matters<\/p>\n
There\u2019s a prevailing myth that we already know everything we need to about cannabis. The truth is far more complicated\u2014and nuanced. There are gaps in our knowledge when it comes to optimal dosing, long-term effects of consumption methods, the efficacy of different strains for different conditions, and interactions with other medications.<\/p>\n
Katharine Neill Harris, a drug policy expert at Rice University, hopes the bill will \u201clead to an increase in rigorous research to inform medical use practice.\u201d In particular, she points to the need for federally sanctioned trials that could explore whether certain cannabinoids are more effective for pain, PTSD, or epilepsy\u2014and in what forms.<\/p>\n
While private-sector research exists, it\u2019s not a substitute for publicly funded, peer-reviewed studies that can shape national healthcare policy and FDA approval processes.<\/p>\n
A Door to Psychedelic Science<\/p>\n
Although cannabis is at the center of the bill\u2019s promotional messaging, the EBDPA would affect all Schedule I substances. That includes psilocybin and MDMA\u2014two drugs currently showing promise in treating PTSD, depression, and substance use disorders in controlled therapeutic settings.<\/p>\n
Without this bill or similar legislation, the federal government is effectively blocked from studying these possibilities. Research institutions must jump through impossible hoops to get approval, and federal grants remain largely out of reach. That means the science emerging from Johns Hopkins, NYU, and MAPS often relies on philanthropy rather than public investment.<\/p>\n
\u201cIf there is evidence to support FDA approval for a Schedule I drug for therapeutic applications,\u201d Harris said, \u201cthis bill would mean that the ONDCP would not have to reflexively oppose it.\u201d<\/p>\n
The Political Reality Check<\/p>\n
Of course, optimism must be tempered by political realism. Aaron Smith, CEO of the National Cannabis Industry Association, is less enthusiastic about the bill\u2019s prospects, calling its passage unlikely \u201cin the hyper-partisan times we live in.\u201d<\/p>\n
Still, there\u2019s a case to be made for bipartisan support. The bill doesn\u2019t call for legalization or even rescheduling\u2014it merely opens the door for federal research to begin. That\u2019s a position that could appeal to cautious moderates and data-driven conservatives alike, particularly those interested in state-level outcomes or cost-benefit analyses related to healthcare and law enforcement.<\/p>\n
\u201cThis bill prioritizes evidence over ideology,\u201d Packer said. \u201cThat alone gives it a fighting chance.\u201d<\/p>\n
If Not Now, When?<\/p>\n
Rescheduling cannabis under the Controlled Substances Act has stalled, particularly since Donald Trump returned to the White House. The Biden administration had moved to reclassify cannabis as a Schedule III substance\u2014a step that would allow for FDA approval of cannabis-based medicines\u2014but that effort is now all but dead.<\/p>\n
By contrast, the EBDPA doesn\u2019t require executive action or complex administrative rulemaking. It\u2019s relatively easy to enact, legally speaking. The challenge is political will.<\/p>\n
And make no mistake: this is a rare moment of alignment between public opinion and policy opportunity. More than 70% of Americans support cannabis legalization. Veterans groups, physicians, civil rights advocates, and law enforcement reformers all want more data. What\u2019s missing is the mechanism.<\/p>\n
A Small Bill That Could Change Everything<\/p>\n
If passed, the EBDPA won\u2019t make headlines like legalization or rescheduling would. But it could quietly change the future of drug policy in the U.S.<\/p>\n
By lifting the muzzle from federal researchers, the bill could unlock a new era of evidence-based regulation, finally allowing us to study\u2014not speculate about\u2014the real impacts of legalization and therapeutic use. It\u2019s not radical. It\u2019s not risky. It\u2019s rational.<\/p>\n
And in 2025, that\u2019s revolutionary enough.<\/p>\n
Courtesy of Cannabistechtoday.com and author Adjoua Kouassi.<\/p>\n","protected":false},"excerpt":{"rendered":"
The Evidence-Based Drug Policy Act of 2025 (EBDPA), introduced by Representatives Dina Titus and Ilhan Omar, doesn\u2019t aim to legalize cannabis or reschedule it. Instead, it proposes something deceptively simple: allow the federal government to study it. In a policy environment where ideology has long outpaced data, this quiet shift could have seismic consequences. The […]<\/p>\n","protected":false},"author":1,"featured_media":316,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"class_list":["post-315","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/thefreeworldremedy.com\/blog\/wp-content\/uploads\/2025\/05\/scales-of-justice.png?fit=800%2C500&ssl=1","jetpack_likes_enabled":true,"jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/posts\/315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/comments?post=315"}],"version-history":[{"count":1,"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/posts\/315\/revisions"}],"predecessor-version":[{"id":317,"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/posts\/315\/revisions\/317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/media\/316"}],"wp:attachment":[{"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/media?parent=315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/categories?post=315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thefreeworldremedy.com\/blog\/wp-json\/wp\/v2\/tags?post=315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}